NCT04242953View on ClinicalTrials.gov

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

October 21, 2022

Study Completion Date

October 21, 2022

Conditions

Healthy Volunteer Study

Interventions

DRUG

SCO-120

"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"

DRUG

matching placebo

"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"

Trial Locations (3)

63141

BioPharma Services USA Inc., Creve Coeur

56529-1342

AXIS Clinicals, Dilworth

ON M9L 3A2

BioPharma Services Inc., Toronto

All Listed Sponsors

lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT04242953 - Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects | Biotech Hunter | Biotech Hunter